Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Inclusion Criteria:

• Hodgkin Lymphoma, intermediate or advanced stage
• Age >60 and <75 years
• ECOG 2 or better
• No major organ dysfunction
• Ability to take aspirin or LMW Heparin

Exclusion Criteria:

• HL as composite lymphoma
• Prior use of lenalidomide
• Prior use of chemo- or radiotherapy